Literature DB >> 22100351

Feasibility, reliability and validity of the Dutch translation of the Anxiety, Depression And Mood Scale in older adults with intellectual disabilities.

Heidi Hermans1, Naftha Jelluma, Femke H van der Pas, Heleen M Evenhuis.   

Abstract

BACKGROUND: The informant-based Anxiety, Depression And Mood Scale was translated into Dutch and its feasibility, reliability and validity in older adults (aged ≥ 50 years) with intellectual disabilities (ID) was studied.
METHOD: Test-retest (n = 93) and interrater reliability (n = 83), and convergent (n = 202 and n = 787), discriminant (n = 288) and criterion validity (n = 288) were studied. Convergent and criterion validity were studied for the Depressed mood and General anxiety subscales. Subgroups based on level of ID and autism have been made to study the criterion validity. Psychiatric diagnoses based on the PAS-ADD Interview were used as gold standard.
RESULTS: All subscales had good internal consistency (α ≥ 0.80), excellent test-retest reliability (ICC ≥ 0.75) and good interrater reliability (ICC ≥ 0.74), except for the Social avoidance subscale (ICC = 0.57). The Depressed mood subscale showed low correlation (r = 0.44) with the self-report Inventory of Depressive Symptomatology, high correlation with the informant-report Signalizing Depression List for people with ID (r = 0.71) and no correlation with the PAS-ADD's sleep disorders subscale (r = 0.15). Its sensitivity ranged from 73 to 80%, and its specificity from 71 to 79%. The General anxiety subscale showed low correlation with the self-report scales: Glasgow Anxiety Scale (r= 0.37) and Hospital Anxiety and Depression Scale (r = 0.41), and no correlation with the sleep disorder subscale (r = 0.02). Its sensitivity ranged from 67 to 100%, and its specificity from 48 to 81%.
CONCLUSIONS: The Dutch translation of the ADAMS is reliable and sufficiently valid to screen for anxiety and depression in older people with ID.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22100351     DOI: 10.1016/j.ridd.2011.09.018

Source DB:  PubMed          Journal:  Res Dev Disabil        ISSN: 0891-4222


  6 in total

Review 1.  Proxy-report in individuals with intellectual disability: A scoping review.

Authors:  Stephanie L Santoro; Karen Donelan; Melissa Constantine
Journal:  J Appl Res Intellect Disabil       Date:  2022-06-08

2.  Validation of a Revised Version of the Center for Epidemiologic Depression Scale for Youth with Intellectual Disabilities (CESD-ID-R).

Authors:  Elizabeth Olivier; Corina Lacombe; Alexandre J S Morin; Simon A Houle; Cynthia Gagnon; Danielle Tracey; Rhonda G Craven; Christophe Maïano
Journal:  J Autism Dev Disord       Date:  2021-10-30

3.  Reliability and validity of the Dutch Anxiety, Depression And Mood Scale in adults aged <50 years with intellectual disabilities.

Authors:  Pauline C M Hamers; Jans S van Ool; Dederieke A M Festen; Jos G M Hendriksen; Patrick J E Bindels; Heidi Hermans
Journal:  J Appl Res Intellect Disabil       Date:  2018-11-20

4.  The occurrence of comorbidities with affective and anxiety disorders among older people with intellectual disability compared with the general population: a register study.

Authors:  Nadia El Mrayyan; Jonas Eberhard; Gerd Ahlström
Journal:  BMC Psychiatry       Date:  2019-06-03       Impact factor: 3.630

5.  Healthy Ageing and Intellectual Disability study: summary of findings and the protocol for the 10-year follow-up study.

Authors:  Marleen J de Leeuw; Alyt Oppewal; Roy G Elbers; Mireille W E J Knulst; Marco C van Maurik; Marjoleine C van Bruggen; Thessa I M Hilgenkamp; Patrick J E Bindels; Dederieke A M Maes-Festen
Journal:  BMJ Open       Date:  2022-02-22       Impact factor: 2.692

6.  The behavioural phenotype of SATB2-associated syndrome: a within-group and cross-syndrome analysis.

Authors:  Stacey Bissell; Chris Oliver; Joanna Moss; Mary Heald; Jane Waite; Hayley Crawford; Vishakha Kothari; Lauren Rumbellow; Grace Walters; Caroline Richards
Journal:  J Neurodev Disord       Date:  2022-03-29       Impact factor: 4.025

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.